Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Biogen Idec was formed on 12th November 2003, following the merger of IDEC Pharmaceuticals Inc and Biogen Inc,
bringing together the complementary strengths of each company.
As a result of the merger, Biogen stockholders received 1.15 shares of Biogen Idec common stock for each share of
Biogen common stock. As a result, Biogen Idec issued approximately 171.9 million shares at a fair value of
approximately US$6.48 billion. In addition, options to purchase Biogen common stock outstanding at 12th November,
2003 were assumed by Biogen Idec and converted into options to purchase approximately 20.7 million shares of
Biogen Idec common stock at a fair value of approximately US$295 million. Biogen paid approximately US$19.8 million
in fees for banking, legal, accounting and tax related services related to the merger. Merger related fees of US$21.5
million paid by Biogen prior to completion of the merger are not included in this amount as they were expensed as
incurred. The total merger purchase price was US$6,795,598.